EPISODE · Apr 2, 2018 · 17 MIN
Optimizing Anticancer Therapy in Prostate Cancer Guideline
from ASCO Guidelines
An interview with Dr. Michael J. Morris from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine on the ASCO clinical practice guideline which addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostate cancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. Read the full guideline at www.asco.org/genitourinary-cancer-guidelines
Embed this episode
NOW PLAYING
Optimizing Anticancer Therapy in Prostate Cancer Guideline
No transcript for this episode yet
Similar Episodes
No similar episodes found.